{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bipolar-disorder/prescribing-information/lamotrigine/","result":{"pageContext":{"chapter":{"id":"587e9545-d869-5933-b101-2407ad59bc52","slug":"lamotrigine","fullItemName":"Lamotrigine","depth":2,"htmlHeader":"<!-- begin field 9cc4f1a3-20f3-426a-b2d4-4f3d8ab4f5b3 --><h2>Lamotrigine</h2><!-- end field 9cc4f1a3-20f3-426a-b2d4-4f3d8ab4f5b3 -->","summary":"","htmlStringContent":"<!-- begin item 44b1be38-1232-4d41-b32c-6baebf0f6de4 --><!-- end item 44b1be38-1232-4d41-b32c-6baebf0f6de4 -->","topic":{"id":"ac644ce3-3932-5e1f-8676-4ebcfb5f240d","topicId":"87d084eb-bc7f-45b7-9384-f490e6417d9d","topicName":"Bipolar disorder","slug":"bipolar-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"3ed6a7a1-589c-57a9-89fd-e61f76a4c198","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"96f8d073-2e2b-55bd-9f94-a0cf336756a7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5a048129-7c1e-5fc5-8a8a-3e91b2be7e18","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61d98476-085c-58c4-b646-093d1564a66c","slug":"changes","fullItemName":"Changes"},{"id":"e8e86070-9a3a-5b97-8a3b-d76771dd7e92","slug":"update","fullItemName":"Update"}]},{"id":"308f8462-ca53-5dee-9a6a-463a88283762","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e56ddcf1-8ade-5c55-ada8-cd9307fa9d45","slug":"goals","fullItemName":"Goals"},{"id":"c9a278dc-a960-595c-90fa-702a979fe434","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6c858f7e-b8a9-5125-9b30-d15ff9489c89","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"caccf5a3-718b-556f-a3d7-e412c84fffec","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1d1a32a6-8f9b-54ef-8db8-35685fd71f28","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"31f4b1ea-76e5-5273-821f-7ba3fd77ac0e","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b529213a-3211-53f9-b870-f03b9a1d30c9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"53fd9729-258a-5bc1-ac8d-c7c2ebdfd92e","slug":"definition","fullItemName":"Definition"},{"id":"0dc41761-cd41-54cc-8277-c96320874497","slug":"causes","fullItemName":"Causes"},{"id":"2c7c3452-f7d6-5a4d-ac13-72ecad737a44","slug":"incidence-prevalence","fullItemName":"Incidence and prevalence"},{"id":"7a53a39d-073b-5a29-b48d-a0ff3049049e","slug":"complications","fullItemName":"Complications"},{"id":"ae1afd6c-efdb-5d1f-82a9-ee9a07103bde","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"45d991bb-5121-511b-a201-826c8297a59d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff54cf2c-7ebb-58b5-a77c-a285db95f263","slug":"suspecting-bipolar-disorder","fullItemName":"Suspecting bipolar disorder"},{"id":"a5cf6d30-ba09-58fa-b2a2-78490ef3dfe6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0c45d8c8-9038-5e75-9637-34b9b70a708f","fullItemName":"Management","slug":"management","subChapters":[{"id":"08d1a671-233b-56fe-9343-455ae9d9457c","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"},{"id":"3168933b-1d1b-56e0-82d5-13b7a4175ed1","slug":"managing-relapse","fullItemName":"Scenario: Managing relapse"},{"id":"7fd5675a-5f41-5662-86a1-dcd7103d1e7b","slug":"routine-bipolar-disorder-review","fullItemName":"Scenario: Routine bipolar disorder review"},{"id":"7cd1d695-071f-5e74-945f-e61927a44a85","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"7be9863d-b620-5545-b0ca-d2a5ea14af95","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d0da96ab-51ae-530a-ac52-76b445fb10a5","slug":"ssris","fullItemName":"SSRIs"},{"id":"7ccedc62-ec67-54d4-a721-f520c7573553","slug":"antipsychotics","fullItemName":"Antipsychotics"},{"id":"587e9545-d869-5933-b101-2407ad59bc52","slug":"lamotrigine","fullItemName":"Lamotrigine"},{"id":"f1925178-1888-5bf8-8868-92a526afff0f","slug":"lithium","fullItemName":"Lithium"},{"id":"1933741e-2f27-57bf-92f1-5d769518344f","slug":"valproate","fullItemName":"Valproate"}]},{"id":"1913037b-d494-5a34-be7c-baf4cb96acd4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"88a92260-20b8-51eb-8b46-3a2409ddf63b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"438d8ad5-e57e-58be-8902-0a3160dc221d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a4449bc7-d64d-5a1c-a07a-b9a548cc3172","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"be352ccd-5a94-556d-b076-f450b54edbfb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"999ad09a-2f9f-562d-9583-938295801e7f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a2be53e8-c67a-5bbd-a684-a352c46d9902","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c4e156df-5e61-50f0-bcf6-60433f5a4e37","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7be9863d-b620-5545-b0ca-d2a5ea14af95","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"5dcaa050-0870-5ad4-a6c3-b20fd26fa09b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 42bcde32-0fa8-4e57-ba0a-aa91015ac49d --><h3>Contraindications and cautions</h3><!-- end field 42bcde32-0fa8-4e57-ba0a-aa91015ac49d -->","summary":"","htmlStringContent":"<!-- begin item 3670ef1e-aac3-458c-8ff9-aa91015ac441 --><!-- begin field f3786eff-98b2-4a70-bdf4-aa91015ac49d --><p><strong>Prescribe lamotrigine with caution to people with:</strong></p><ul><li>Myoclonic seizures (may be exacerbated).</li><li>Parkinson’s disease (may be exacerbated).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field f3786eff-98b2-4a70-bdf4-aa91015ac49d --><!-- end item 3670ef1e-aac3-458c-8ff9-aa91015ac441 -->","subChapters":[]},{"id":"7a61ba1a-796f-5c1f-983f-a1a6cab89995","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3d9dcd89-2a89-406b-8767-61432ea9fbcd --><h3>What are the adverse effects of lamotrigine?</h3><!-- end field 3d9dcd89-2a89-406b-8767-61432ea9fbcd -->","summary":"","htmlStringContent":"<!-- begin item 3c335fdd-a192-436c-a13d-217336ab27a6 --><!-- begin field a2c576e0-abf7-4f25-b225-0c26fba8d7d7 --><p><strong>Adverse effects of lamotrigine include:</strong></p><ul><li><strong>Skin rash</strong><strong>:</strong><ul><li><strong><strong>All </strong>people (adults and children) who develop a rash should be promptly evaluated and lamotrigine withdrawn immediately unless the rash is clearly not drug related.</strong></li><li>Rash has been reported in up to 12% of people taking lamotrigine in clinical trials . These rashes were maculopapular in appearance, generally appeared within 8 weeks of starting treatment, and resolved on withdrawal of lamotrigine.</li><li>Serious, potentially life threatening skin rashes, including Stevens–Johnson syndrome, toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported. Stevens–Johnson syndrome has been reported in 0.3% of adults and 0.8% of children.</li><li>In children, the initial presentation of a rash can be mistaken for an infection; clinicians should consider the possibility of a drug reaction in children that develop symptoms of rash and fever during the first 8 weeks of therapy.</li><li>Factors associated with increased risk of serious skin reactions include:<ul><li>Concomitant use of valproate, initial lamotrigine dosage higher than recommended, and more rapid dose escalation than recommended.</li><li>Rash is sometimes associated with hypersensitivity syndrome (fever, lymphadenopathy, hepatic dysfunction, blood disorders, disseminated intravascular coagulation, and multiorgan dysfunction) and is more common in people with a history of allergy or rash from other antiepileptic drugs.</li></ul></li></ul></li><li><strong>Other adverse effects reported include </strong>nausea, vomiting, diarrhoea, dry mouth, aggression, agitation, headache, dizziness, drowsiness and insomnia, diplopia, blurred vision, conjunctivitis, confusion, nightmares, and hallucinations.</li><li><strong>Some rarely reported adverse effects include</strong><strong>:</strong><ul><li>Hypersensitivity syndrome.</li><li>Photosensitivity.</li><li>Blood disorders: leucopenia, thrombocytopenia, pancytopenia.</li><li>Lupus-like reactions.</li></ul></li><li><strong>There is a small risk of suicidal thoughts and behaviour, which may be seen as early as one week after starting treatment.</strong><ul><li>People taking lamotrigine and healthcare professionals should be alert to any mood changes, distressing thoughts, or feelings about suicide or harming themselves at any point during treatment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI, 2021</a>]</p><!-- end field a2c576e0-abf7-4f25-b225-0c26fba8d7d7 --><!-- end item 3c335fdd-a192-436c-a13d-217336ab27a6 -->","subChapters":[]},{"id":"39358f55-b63b-5d45-a8e5-17ca77193e90","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 2f0364fc-1ffd-44bd-a62e-9f8a3753520d --><h3>What are the drug interactions of lamotrigine?</h3><!-- end field 2f0364fc-1ffd-44bd-a62e-9f8a3753520d -->","summary":"","htmlStringContent":"<!-- begin item 4bf00136-7316-4622-acb0-9e4aa345d2ec --><!-- begin field 5ffea6fb-e7fa-4725-b883-b2771d2e153c --><p><strong>Key drug interactions with lamotrigine include:</strong></p><ul><li>CNS depressants — enhanced effect when co-administered with lamotrigine.</li><li>Carbamazepine, rifampicin, phenytoin, primidone, oestrogens, and progestogens —plasma concentration of lamotrigine is reduced and the dose of may therefore need to be increased.\\</li><li>Desmopressin — Lamotrigine is predicted to increase the risk of hyponatraemia when given with desmopressin. Manufacturer advises monitor serum sodium.</li><li>Ritonavir — Ritonavir slightly decreases the exposure to lamotrigine. Manufacturer advises monitor lamotrigine concentration.</li><li>Valproate — Plasma concentration of lamotrigine is increased by valproate. Manufacturer advises adjust lamotrigine dose and monitor for rash.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bipolar-disorder/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 5ffea6fb-e7fa-4725-b883-b2771d2e153c --><!-- end item 4bf00136-7316-4622-acb0-9e4aa345d2ec -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}